Wyeth extends Curis funding to continue development of Hedgehog agonist for neurological disorders

By E. Janene Geiss

Philadelphia, Nov. 21 - Curis, Inc. said Monday that Wyeth has extended its funding to continue development of the Hedgehog agonist for neurological disorders.

By exercising this option, Wyeth has agreed to extend the research term by one year to Feb. 9, 2007 from the previous Feb. 9, 2006 termination, officials said. The agreement dates from 2004.

Curis said it expects Wyeth to select a development candidate in the next 12 to 18 months and file an Investigational New Drug application about a year later, officials said.

"We are encouraged by the continued dedication that Wyeth has shown to the Hedgehog agonist program for neurological disorders. The extension of funding for the program serves as a validation of the progress made to date on this program, and we look forward to working with Wyeth to select a development candidate for stroke and other neurological disorders," Curis president and chief executive officer Daniel R. Passeri said in the release.

Wyeth entered into an agreement with Curis in January 2004 to continue development of drug candidates to treat neurological diseases and other potential indications.

Curis is a Cambridge, Mass., therapeutic drug development company focused on regulatory pathways that control repair and regeneration.

Wyeth, based in Madison, N.J., is a research-driven pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.